Table I.
Clinical characteristics of 72 patients with advanced non-small cell lung cancer carrying EGFR mutation.
| Clinical characteristics | Exon 19 deletions (n=37) | An exon 21 mutation (n=35) | P-value |
|---|---|---|---|
| Sex | 0.884 | ||
| Male | 10 (27.0) | 10 (28.6) | |
| Female | 27 (73.0) | 25 (71.4) | |
| Age (years) | 0.995 | ||
| <70 | 18 (48.6) | 17 (48.6) | |
| ≥70 | 19 (51.4) | 18 (51.4) | |
| Histological type | 0.820 | ||
| Adenocacinoma | 31 (83.8) | 30 (85.7) | |
| Squamous | 6 (16.2) | 5 (14.3) | |
| Clinical stage | 0.984 | ||
| IIIB | 17 (45.9) | 16 (45.7) | |
| IV | 20 (54.1) | 19 (54.3) | |
| PS score | 0.974 | ||
| 0 or 1 | 16 (43.2) | 15 (42.9) | |
| 2 | 21 (56.8) | 20 (57.1) | |
| Smoking history | 0.866 | ||
| Smoker | 8 (21.6) | 7 (20.0) | |
| Non-smoker | 29 (78.4) | 28 (80.0) | |
| EGFR-TKI | 0.642 | ||
| Gefitinib | 20 (54.1) | 17 (48.6) | |
| Erlotinib | 17 (45.9) | 18 (51.4) | |
| Sequential surgery | 0.968 | ||
| Surgery | 1 | 1 | |
| Non-surgery | 36 | 34 | |
| Sequential chemotherapy | 0.925 | ||
| Chemotherapy | 5 | 32 | |
| Non-chemotherapy | 5 | 30 |
Data are presented as n or n (%). EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PS, performance status